Profile of Aclidinium Bromide in the Treatment of Chronic Obstructive Pulmonary Disease

Overview

Journal Int J Chron Obstruct Pulmon Dis

Publisher Dove Medical Press

Specialty Pulmonary Medicine

Date 2011 Oct 18

PMID 22003291

Citations 7

Authors

Michael W Sims

Reynold A Panettieri Jr

Affiliations

Soon will be listed here.

Abstract

Bronchodilators provide the mainstay of pharmacologic therapy for chronic obstructive pulmonary disease (COPD), and anticholinergic bronchodilators, in particular, appear to be the most effective. There are currently two anticholinergic agents available in the US for the treatment of COPD (ipratropium bromide and tiotropium bromide), but several others are in various stages of development. Aclidinium bromide, a novel, long-acting, anticholinergic bronchodilator, is currently in Phase III trials for the management of COPD. Available evidence suggests that aclidinium is a safe and well tolerated drug with a relatively rapid onset and a sufficient duration of action to provide once-daily dosing. This article will provide a pharmacologic profile of aclidinium bromide and review the preclinical and clinical studies evaluating its safety and efficacy in the treatment of COPD.

Citing Articles

Romanian clinical guideline for diagnosis and treatment of COPD.

Ulmeanu R, Fildan A, Rajnoveanu R, Fira-Mladinescu O, Toma C, Nemes R J Int Med Res. 2020; 48(8):300060520946907.

PMID: 32815452 PMC: 7444126. DOI: 10.1177/0300060520946907.

Combined aclidinium bromide and long-acting beta2-agonist for chronic obstructive pulmonary disease (COPD).

Ni H, Moe S, Soe Z, Myint K, Viswanathan K Cochrane Database Syst Rev. 2018; 12:CD011594.

PMID: 30536566 PMC: 6517126. DOI: 10.1002/14651858.CD011594.pub2.

Diagnosis and pharmacotherapy of stable chronic obstructive pulmonary disease: the finnish guidelines.

Kankaanranta H, Harju T, Kilpelainen M, Mazur W, Lehto J, Katajisto M Basic Clin Pharmacol Toxicol. 2014; 116(4):291-307.

PMID: 25515181 PMC: 4409821. DOI: 10.1111/bcpt.12366.

Aclidinium bromide for stable chronic obstructive pulmonary disease.

Ni H, Soe Z, Moe S Cochrane Database Syst Rev. 2014; (9):CD010509.

PMID: 25234126 PMC: 8922974. DOI: 10.1002/14651858.CD010509.pub2.

Emerging Therapeutic Options for the Management of COPD.

Reid D, Pham N Clin Med Insights Circ Respir Pulm Med. 2013; 7:7-15.

PMID: 23641160 PMC: 3629926. DOI: 10.4137/CCRPM.S8140.

References

Al-Showair R, Tarsin W, Assi K, Pearson S, Chrystyn H . Can all patients with COPD use the correct inhalation flow with all inhalers and does training help?. Respir Med. 2007; 101(11):2395-401. DOI: 10.1016/j.rmed.2007.06.008. View

Schelfhout V, Ferrer P, Jansat J, Peris F, Garcia Gil E, Pauwels R . Activity of aclidinium bromide, a new long-acting muscarinic antagonist: a phase I study. Br J Clin Pharmacol. 2010; 69(5):458-64. PMC: 2856046. DOI: 10.1111/j.1365-2125.2010.03622.x. View

Chanez P, Burge P, Dahl R, Creemers J, Chuchalin A, Lamarca R . Aclidinium bromide provides long-acting bronchodilation in patients with COPD. Pulm Pharmacol Ther. 2009; 23(1):15-21. DOI: 10.1016/j.pupt.2009.08.001. View

Prat M, Fernandez D, Buil M, Crespo M, Casals G, Ferrer M . Discovery of novel quaternary ammonium derivatives of (3R)-quinuclidinol esters as potent and long-acting muscarinic antagonists with potential for minimal systemic exposure after inhaled administration: identification of.... J Med Chem. 2009; 52(16):5076-92. DOI: 10.1021/jm900132z. View

Alberti J, Martinet A, Sentellas S, Salva M . Identification of the human enzymes responsible for the enzymatic hydrolysis of aclidinium bromide. Drug Metab Dispos. 2010; 38(7):1202-10. DOI: 10.1124/dmd.109.031724. View

ODonnell D, Sciurba F, Celli B, Mahler D, Webb K, Kalberg C . Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD. Chest. 2006; 130(3):647-56. DOI: 10.1378/chest.130.3.647. View

Damera G, Jiang M, Zhao H, Fogle H, Jester W, Freire J . Aclidinium bromide abrogates allergen-induced hyperresponsiveness and reduces eosinophilia in murine model of airway inflammation. Eur J Pharmacol. 2010; 649(1-3):349-53. DOI: 10.1016/j.ejphar.2010.09.043. View

Maltais F, Hamilton A, Marciniuk D, Hernandez P, Sciurba F, Richter K . Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD. Chest. 2005; 128(3):1168-78. DOI: 10.1378/chest.128.3.1168. View

Sentellas S, Ramos I, Alberti J, Salva M, Anton F, Miralpeix M . Aclidinium bromide, a new, long-acting, inhaled muscarinic antagonist: in vitro plasma inactivation and pharmacological activity of its main metabolites. Eur J Pharm Sci. 2010; 39(5):283-90. DOI: 10.1016/j.ejps.2010.01.004. View

10.

Wessler I, Kirkpatrick C . The Non-neuronal cholinergic system: an emerging drug target in the airways. Pulm Pharmacol Ther. 2002; 14(6):423-34. DOI: 10.1006/pupt.2001.0313. View

11.

Barnes P . The pharmacological properties of tiotropium. Chest. 2000; 117(2 Suppl):63S-6S. DOI: 10.1378/chest.117.2_suppl.63s. View

12.

Rennard S, Serby C, Ghafouri M, Johnson P, Friedman M . Extended therapy with ipratropium is associated with improved lung function in patients with COPD. A retrospective analysis of data from seven clinical trials. Chest. 1996; 110(1):62-70. DOI: 10.1378/chest.110.1.62. View

13.

Pauwels R, Buist A, Calverley P, Jenkins C, Hurd S . Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med. 2001; 163(5):1256-76. DOI: 10.1164/ajrccm.163.5.2101039. View

14.

Brand P, Meyer T, Weuthen T, Timmer W, Berkel E, Wallenstein G . Lung deposition of radiolabeled tiotropium in healthy subjects and patients with chronic obstructive pulmonary disease. J Clin Pharmacol. 2007; 47(10):1335-41. DOI: 10.1177/0091270006295788. View

15.

Butler J, Caro C, Alcala R, DuBois A . Physiological factors affecting airway resistance in normal subjects and in patients with obstructive respiratory disease. J Clin Invest. 1960; 39:584-91. PMC: 293341. DOI: 10.1172/JCI104071. View

16.

Gross N, Co E, Skorodin M . Cholinergic bronchomotor tone in COPD. Estimates of its amount in comparison with that in normal subjects. Chest. 1989; 96(5):984-7. DOI: 10.1378/chest.96.5.984. View

17.

Tashkin D, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S . A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008; 359(15):1543-54. DOI: 10.1056/NEJMoa0805800. View

18.

MAESEN F, Smeets J, Sledsens T, Wald F, CORNELISSEN P . Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Dutch Study Group. Eur Respir J. 1995; 8(9):1506-13. View

19.

de Koning J, van der Mark T, Coenegracht P, Tromp T, Frijlink H . Effect of an external resistance to airflow on the inspiratory flow curve. Int J Pharm. 2002; 234(1-2):257-66. DOI: 10.1016/s0378-5173(01)00969-3. View

20.

Jansat J, Lamarca R, Garcia Gil E, Ferrer P . Safety and pharmacokinetics of single doses of aclidinium bromide, a novel long-acting, inhaled antimuscarinic, in healthy subjects. Int J Clin Pharmacol Ther. 2009; 47(7):460-8. DOI: 10.5414/cpp47460. View